Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al. | Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia (Cancer Cell International, (2023), 23, 1, (202), 10.1186/s12935-023-03057-8) | 2025 |
|
Erhan Aptullahoglu
Mohammed Howladar
Dr Jonathan Wallis
Dr Helen Marr
Professor Julie Irving
et al. | Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia | 2025 |
|
Dr Hayden Bell
Dr Helen Blair
Samantha Jepson Gosling
Dr Martin Galler
Dan Astley
et al. | Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia | 2024 |
|
Dr Dino Masic
Dr Hayden Bell
Dr Frederik van Delft
Professor Julie Irving
| Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target | 2024 |
|
Dr Jill Hunter
Dr Elaine Willmore
Professor Julie Irving
Dr Stephany Veuger
| Correction to: NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229) | 2023 |
|
Dr Richard Gallon
Rachel Phelps
Christine Hayes
Dr Dino Masic
Professor Julie Irving
et al. | Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia | 2023 |
|
Dr Dino Masic
Kayleigh Fee
Dr Hayden Bell
Marian Case
Juan Ojeda Garcia
et al. | Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia | 2023 |
|
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al. | Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia | 2023 |
|
Professor Julie Irving
| Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature | 2022 |
|
Dr Tobias Menne
Professor Julie Irving
Professor Ruth Plummer
Dr Geoff Shenton
Professor Gareth Veal
et al. | Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial | 2022 |
|
Professor Anthony Moorman
Professor Julie Irving
| Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials | 2021 |
|
Dr Amir Enshaei
Dr Sirintra Nakjang
Lynne Minto
Professor Julie Irving
Beth Poole
et al. | The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia | 2021 |
|
Marian Case
Dr Dino Masic
Dr David Jamieson
Dr Frederik van Delft
Professor Andrew Filby
et al. | Label-Free Leukemia Monitoring by Computer Vision | 2020 |
|
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al. | Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM | 2019 |
|
Dr Rosanna Jackson
Philip Berry
Julie Errington
Professor Julie Irving
Professor Gareth Veal
| Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial | 2019 |
|
